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ABSTRACT: Fibrinogen concentration is a major determinant of both
clotting and bleeding risk. Clotting and bleeding disorders cause extensive
morbidity and mortality, particularly in resource-poor and emergency
settings. This is exacerbated by a lack of timely intervention informed by
measurement of fibrinogen levels under conditions such as thrombosis or
postpartum haemorrhage. There is an absence of simple, rapid, low-cost,
and sustainable diagnostic devices for fibrinogen measurement that can be
deployed in such environments. Paper-based analytical devices are of
significant interest due to their potential for low-cost production, ease of
use, and environmental sustainability. In this work, a device for measuring
blood plasma fibrinogen using chromatography paper was developed. Wax
printing was used to create hydrophobic structures to define the test
channel and sample application zone. Test strips were modified with
bovine thrombin. Plasma samples (22 μL) were applied, and the flow rate
was monitored over 5 min. As the sample traversed the strip, clotting was induced by the conversion of soluble fibrinogen to
insoluble fibrin. The flow rate and distance travelled by the sample were dependent on fibrinogen concentration. The device was able
to measure fibrinogen concentration in the range of 0.5−7.0 ± 0.3 mg/mL (p < 0.05, n = 24) and had excellent correlation with
laboratory coagulometry in artificial samples (r2 = 0.9582, n = 60). Devices were also stable at 4−6 °C for up to 3 weeks.
Fibrinogen is a 340 kDa glycoprotein that circulates inblood in a normal range of 2−4 mg/mL. Its conversion to
fibrin is the basis of clot formation during coagulation.1
Fibrinogen is also involved in primary haemostasis where it
facilitates platelet adhesion and aggregation at the wound site.2
Low fibrinogen levels may result in postpartum haemorrhage,3
pregnancy loss, and intracranial and joint bleeding, while
elevated fibrinogen may be a risk factor in thrombophilia.4
Fibrinogen is an important biomarker for assessing haemostatic
function and diagnosing haemostatic disorders. Bleeding and
clotting disorders cause extensive morbidity and mortality,
especially in resource-poor settings, which may lack access to
suitable testing methods. There are several routine hospital-
based methods for fibrinogen in whole blood and plasma
including the Clauss assay,5 viscoelastic assays,6,7 dry
haematology methods,8 and prothrombin time-derived fibri-
nogen assay.5 However, such approaches are not suitable for
point-of-care use in resource-limited environments. A rapid,
inexpensive, and easy-to-use fibrinogen assay would signifi-
cantly enhance the diagnosis and treatment of coagulation
disorders.
Lateral flow assays (LFAs) have been widely used in point-
of-care diagnostic applications.9 The combination of lateral
flow to drive assay processes with visual reading of the test
result produces low cost, easy-to-use tests with no
instrumentation. LFA devices based on polymer micro-
fabrication have been developed for the measurement of
fibrinogen.4 While devices such as these may be effective for
instrument-free point-of-care diagnostics, they still lack
environmental sustainability and may result in the accumu-
lation of plastics in the environment. Paper-based LFAs based
predominantly on nitrocellulose substrates are used widely for
many rapid assays for pregnancy10 and COVID-19.11 Porous
paper, for example, chromatographic paper, has re-emerged as
an attractive substrate in bioanalytical devices because of its
many positive features including very low cost, abundant
availability in many forms, biocompatibility, biodegradability,
disposability, ease of modification, and controlled porosity for
driving fluid flow.12,13 Although in use since the 1950s for the
determination of glucose levels in urine,12 there has been a
significant resurgence in cellulose paper-based technologies
and devices in recent years due to these benefits, and such
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devices are again being widely studied in many applications.
The application of paper-based devices in clinical diagnostics,
including blood coagulation testing, has been recently
reviewed.14
Paper-based devices have recently been applied to fibrinogen
measurement. An initial approach employed a vertically
suspended paper substrate, with fibrinogen levels determined
from the distance travelled by the sample up the strip.15
However, the orientation of the device and the need for a fluid
reservoir make it impractical for point-of-care use. Another
approach utilized the permeability of the paper to fibrinogen.
Increased fibrinogen concentration led to a decrease in
permeability and therefore reduced the distance travelled by
the sample. This method could measure fibrinogen in both
plasma and whole blood and had an assay time of 4 min but
was only suitable for samples with low fibrinogen concen-
trations (<1.6 mg/mL).16
A similar approach exploited the resulting differences in
hydrophobicity of the paper when exposed to samples of
different fibrinogen concentrations, which altered the distance
travelled by a dye applied to the paper following sample
application.17 This method could only measure fibrinogen at
<2 mg/mL. Both methods require multistep procedures and
have the potential to be prone to many interferences such as
variations in sample viscosity. Dielectrophoresis has been
recently used in conjunction with a paper-based assay for
measuring fibrinogen.18 The device had a dynamic range from
1.27 to 5.08 mg/mL, high precision, and good agreement with
well-established routine laboratory methods. However, it
required complex instrumentation and fabrication method-
ologies, making it unsuitable for use in low-resource environ-
ments. There is still a significant need for simple, robust, and
sustainable devices for measuring fibrinogen in low-resource
and emergency settings.
In this work, a paper-based lateral flow device was developed
for the measurement of fibrinogen. The device employed wax-
printed paper-based strips to define microfluidic channels, with
thrombin deposited as a coagulation reagent. The device was
rigorously optimized for measurement across a wide dynamic
assay range and validated using coagulometry.
■ MATERIALS AND METHODS
Materials. Whatman no. 1 chromatography paper (460 ×
570 mm, 1001-917), Chromozym TH, and lyophilized
fibrinogen from human plasma (F3879) were from Sigma-
Aldrich, UK. Lyophilized bovine thrombin (50 NIH units/mL)
was from Clauss Fibrinogen 50 kit (5556), and calibration
plasma containing approx. 2.8 mg/mL fibrinogen (5185) was
from Helena Biosciences, UK. Defibrinated plasma (approx.
1.5 mg/mL fibrinogen) was purchased from BioIVT, UK,
while HemosiL low-fibrinogen control plasma with approx.
0.75 mg/mL fibrinogen (0020004200) was from Instrumenta-
tion Laboratory, UK. Yumizen G FIB 2 (130036383) and
Yumizen G imidazol (130036385) reagents were from Horiba,
UK. Aluminum foil Mylar bags (X000Y9UA0L, 12 × 8 cm)
were from Fresherpack, UK, while desiccant silica gel sachets
(10 g) were from CelloExpress.
Device Fabrication. Whatman no. 1 chromatography
paper was cut into A4 sheets. Lateral flow strip configurations
were designed using Microsoft PowerPoint 2016 and printed
using a ColorQube 8570 wax printer (Xerox Corporation,
Malaysia). Strip designs were typical of that shown in Figure 1,
with a circular sample application zone and a linear test
channel. Two designs were employed in this work: 5 × 80 mm
and 3 × 36 mm. The printed strips were heated at 100 °C for 2
min to melt the wax and form a hydrophobic seal19 and were
then cut from the sheet.
Paper-based strips were suspended on a wire rack for
application of thrombin reagent. Lyophilized bovine thrombin
was reconstituted and diluted with deionized water and activity
was measured using a chromogenic assay.20 Thrombin in the
range of 10−50 NIH units/mL was deposited onto strips at the
sample application zone and typically allowed drying for
approx. 40 min at room temperature. A final thrombin
concentration of 30 NIH units/mL was used for assay
validation.
Preparation of Fibrinogen Standards and Artificial
Samples. Assay development and optimization was typically
performed using human plasma with a normal concentration of
fibrinogen (approx. 2.8 mg/mL). For calibration, fibrinogen
standards in the range of 0.8−7.4 mg/mL were prepared by
reconstituting a low fibrin content plasma (0.8 mg/mL) and
dissolving lyophilized fibrinogen in plasma with 1.5 mg/mL.
For device validation, artificial plasma samples were con-
structed from commercial materials. Twenty artificial plasma
samples of unknown concentration were prepared in the low
(eight samples of approx. 1 mg/mL), normal (eight samples of
approx. 3 mg/mL), and high fibrinogen concentration (four
samples of approx. 5 mg/mL) ranges.
Determination of Fibrinogen Concentration. The
concentration of fibrinogen in the calibration standards and
artificial samples was determined using the Yumizen G200
coagulation analyzer (Horiba, UK). Samples were diluted 1 in
5 (≤1.0 g/L fibrinogen), 1 in 10 (1 to 5 g/L fibrinogen), or 1
in 20 (≥5 g/L fibrinogen) in imidazole buffer, according to the
manufacturer’s instructions.
Storage of Strips. For storage and stability studies, the
assay strips were placed in aluminum/Mylar foil bags with 10 g
of silica gel desiccant sachets and sealed under partial vacuum.
Flow Rate Measurements. For testing, strips were placed
inside an ad hoc 3D-printed holder in which the wax edges of
the strips were placed on elevated rails, allowing the paper strip
to be freely suspended (Figure 1). The 3D holder had an
opening in the top to allow sample deposition and visual
monitoring of fluid flow. The holder was also equipped with a
Figure 1. Paper-based lateral flow device for measuring fibrinogen in
plasma. (Top) Paper strip design layout; (Middle) design layout of
strip in the holder; and (Bottom) photograph of the strip suspended
in the holder.
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millimetric scale to measure the distance travelled by the
sample. All flow rate measurements were performed at 37 °C
on a flat heating block on which the strip holder was placed.
Sample reagents were also pre-equilibrated for 5 min before
use. Samples were applied to the sample application zone, and
flow rates were captured using a video recorder, typically for 5
min.
■ RESULTS AND DISCUSSION
The main types of paper used as substrates in analytical devices
are cellulose-based chromatography paper and nitrocellulose.21
Chromatography paper is a low-cost, biodegradable cellulosic
material and was selected as preferable for use in this work due
to these properties. With regard to deposition of assay reagents
onto paper substrates, several methods have been used, such as
drop-casting, inkjet printing, and spray-coating.13 While
automated techniques such as inkjet printing and spray-coating
allow a great deal of control and precision for scale-up and
mass production, they add significant complexity to the
development process, while drop-casting is simple and highly
effective and was effectively employed throughout this work.
Effect of the Sample and Reagent Composition on
the Sample Flow Rate. To develop a blood coagulation
assay device based on lateral flow principles, it is essential to
account for all factors that might influence the fluid dynamics
of the sample. In the case of this device, the most significant
influences on the sample flow rate are likely to be the impact of
coagulation itself, the viscosity of the sample, and the
hydrophobicity, wettability and solubility properties of the
substrate and any deposited reagents as they come into contact
with the advancing sample.
To determine whether any effects on flow rate were as a
result of coagulation, viscosity, or other factors, a number of
clotting and nonclotting controls were performed to quantify
these. With respect to sample viscosity and appropriate
controls, human plasma viscosity is typically in the range of
1.1−1.3 mPa s at 37 °C,22 while serum is 1.4 to 1.8 mPa23 and
so have the potential to act as positive (clotting) and negative
(nonclotting) controls, respectively. However, care should be
taken with serum as a negative control due to the potential
presence of residual fibrinogen and activated coagulation
factors.24 Preliminary studies had investigated the appropriate
volumes of assay reagents and test samples to use in
conjunction with the paper-based assay strips, which would
sufficiently wet but not oversaturate the entire strip. These
were 90 and 70 μL, respectively, for channels of 5 × 80 mm.
Figure 2. Flow rates of sample viscosity and clotting controls (70 μL) on (A) buffer-modified and (B) thrombin-modified strips. Paper assay strips
(5 × 80 mm) were modified with 90 μL of (A) Owren’s buffer or (B) thrombin (50 NIH/mL).
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Strips were modified with 90 μL of either Owren’s buffer or
thrombin at an initial concentration of 50 NIH/mL. Sample
viscosity and clotting controls of water, human plasma, and
serum (70 μL) were applied to modified, dried strips, and the
flow rates were measured (Figure 2). The flow rate of all
samples was reduced on the thrombin-modified strips (Figure
2B) in comparison with buffer-modified strips (Figure 2A),
demonstrating the impact of hydrophobicity, wetting, and
solubility effects on flow dynamics. The flow rate of water was
the greatest on both surfaces, due to its lower viscosity. While
plasma flow rates were lower than serum on both surfaces, this
difference was significantly greater on the thrombin-modified
strips, which could be attributed to clotting and which
suggested a dynamic assay measurement range under these
assay conditions of approx. 12 mm between clotting and
nonclotting controls.
Assay Optimization of Thrombin Concentration and
Sample Volume. The assay was further miniaturized to strip
dimensions of 3 × 36 mm and sample and reagent volumes of
20 and 27 μL, respectively, reducing material and reagent
usage. Following the initial investigation of thrombin at 50
NIH/mL, further analysis was performed to determine the
effect of thrombin concentration on assay performance. The
flow rates of human plasma were analyzed on strips modified
with thrombin at 10 to 50 NIH/mL (Figure 3A). The plasma
flow rate and the distance travelled by the sample after 5 min
were inversely proportional to thrombin concentration (Figure
3B), demonstrating more rapid fibrin clot formation and arrest
of flow in the presence of higher thrombin concentrations.
While the flow rate and distance travelled were the lowest
for 50 NIH/mL, the overall response to thrombin concen-
tration was curvilinear, with only fractional decreases between
30 and 40 NIH/mL, suggesting that at 50 NIH/mL, the effect
on clotting was close to maximum. However, while 50 NIH/
mL might be close to optimal for assay speed, it might not be
so for other assay parameters such as range, sensitivity,
linearity, and precision. Normal human plasma, such as the one
used here, has a fibrinogen concentration of approx. 2.8 mg/
mL.25 However, under hypo- and hyperfibrinogenemic
conditions, this can vary from <1 to >5 mg/mL.26,27 It is
critical that optimization studies ensure that the assay can
operate across this range. Optimization of thrombin concen-
tration solely at 2.8 mg/mL fibrinogen might limit assay range,
particularly at lower fibrinogen concentrations.
The effect of thrombin activity on assay performance was
evaluated at fibrinogen concentrations of 1.47 (low), 3.70
(normal), and 6.36 (high) mg/mL and their analytical
performance parameters are summarized in Table 1. The
assay at 30 NIH/mL had the highest sensitivity and best
precision, while also having good linearity, and so was adopted
for further assay development. Higher activity of thrombin
leads to faster clotting rates but may have the overall effect of
narrowing the dynamic range and reducing assay sensitivity.
Lower concentration of thrombin, on the other hand, may
improve sensitivity but with reduced precision. Thrombin at 30
NIH/mL appeared to be in sufficient excess over fibrinogen
across the full assay range.
Assays Based on 20 μL Fibrinogen Standards of 1.47,
3.70, and 6.36 mg/mL. Another parameter critical to
analytical performance is sample volume. Minimizing sample
volume is a key parameter to reduce the impact of testing on
patients. However, reducing sample volume can lead to
increased errors in the volume of the sample delivered to
point-of-care devices.28 Analytical methods require precisely
optimized sample volumes, which were investigated here. For
this assay, in particular, reduced sample volume is likely to lead
to reduced linearity and sensitivity, while increased sample
volumes may encourage bulk flow along the strip, rather than
capillary action, which may reduce precision. From preliminary
studies, the optimum sample volume seemed to lie between 20
and 30 μL. Sample volumes of 20, 22, 24, and 26 μL were
investigated at three fibrinogen concentrations and their
analytical parameters are summarized in Table 2. The
sensitivity indicated by the slope, the linearity indicated by
the correlation coefficient (r2), and the precision indicated by
% CV were considered indicators of performance and hence
used here in the optimization of sample volume, reagent
Figure 3. (A) Flow rates of human plasma (20 μL) on strips (3 × 36
mm) modified with 27 μL of thrombin at 10−50 NIH/mL. (B) Effect
of thrombin activity on the distance travelled by plasma samples at 37
°C.
Table 1. Analytical Performance Parameters for Fibrinogen
Calibration Assays Across a Range of Thrombin
Concentrations
thrombin (NIH/mL) slope (mg/mL/mm) r2 CV (%)
20 −4.379 0.842 10.29
30 −6.449 0.999 5.88
40 −5.427 0.947 13.24
50 −4.059 0.985 16.52
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activity, and reagent volume. A 26 μL sample volume achieved
good sensitivity (slope = −6.561) but poor linearity (r2 =
0.680) and precision (CV = 13.49%). A sample volume of 24
μL gave the best linearity (r2 = 0.999), although poor precision
(CV = 11.57%). With a slope of −5.373, an r2 of 0.954, and a
CV of 4.5%, a 22 μL sample volume appeared to have the best
combination of good sensitivity, linearity, and precision and
was therefore used for final assay demonstration. The
performance parameters of 20 μL sample volume were all
below those of 22 μL.
Assays Based on 30 NIH/mL Thrombin and Fibri-
nogen Standards of 1.10, 2.84, and 5.68 mg/mL. Final
Assay Calibration. Fibrinogen standards (22 μL) with
concentrations in the range 0.87−7.4 mg/mL (as determined
by Yumizen G200) were tested on paper-based strips modified
with 30 NIH/mL thrombin (27 μL) (n = 3) (Figure 4). The
distance travelled at 300 s was from 20.33 mm at 0.87 mg/mL
to 9.50 mm at 7.4 mg/mL. The response was curvilinear, with
excellent fit to a semilogarithmic plot with a slope of −5.058
and an r2 of 0.9822. Min., max., and mean coefficients of
variation (n = 3) were 1.84, 9.67, and 5.19%, respectively. At
95% confidence, a measurement of 2.8 mg/mL would be
within the range of 2.5−3.2 mg/mL.
Assay Validation. Validation of the assay was performed
during the global COVID-19 pandemic. As a result, there was
no access to clinical samples for validation studies. To
overcome this, artificial plasma samples were constructed
from combinations of commercial materials from various
sources.
To validate the device for measuring fibrinogen in human
plasma, 20 plasma samples were prepared using mixtures of
low- and normal-fibrinogen plasmas, as well as plasmas
supplemented with lyophilized fibrinogen to create unknowns
with approximate fibrinogen concentrations in the region of 1,
3, and 5 mg/mL.
Each sample was tested simultaneously with the paper-based
device (n = 3 repeats), applying the calibration curve
established in Figure 4, and with the Yumizen coagulation
analyzer G200. The results from the two methods were
compared using linear least-squares regression (Figure 5A) and
Bland−Altman analysis (Figure 5B). There was excellent
agreement between the developed and reference method, with
a slope of 1.03, a very small offset of 0.02 mg/mL, and good
linearity across the analytical range from approx. 1 to 5 mg/mL
with a correlation coefficient of 0.9582.
With a wide dynamic range of 0.5−7 mg/mL, coupled with
adequate agreement with a well-established routine reference
method, the performance of this device is excellent compared
to similar methods recently published. It was capable of
reliable measurement of fibrinogen at all concentrations across
the full range found in human plasma and is suitable for both
hyper- and hypofibrinogenemic conditions, which is in contrast
to the very narrow assay range of other recent work.16,17 In
addition, the method used here was a simple, robust, and single
step, making it more user-friendly, while its design makes it
less-prone to errors and interference. It is also compact,
portable, and instrument-free, making it highly suited to point-
of-care application.
Storage Stability and Operating Temperature. A major
challenge for diagnostic devices is their stability in a range of
operational conditions. Packaging and storage can add cost and
complexity to device production and usage, and devices need
to withstand variations in temperature and humidity over
prolonged periods of time. To assess device stability, assay
strips were prepared, placed in sealed aluminum foil pouches
with desiccant, and stored for up to 28 days in a range of
storage temperatures. Strips were then tested for their flow
rates and clotting distances using normal plasma (Table 3).
The distance travelled by plasma on strips stored in the
fridge and freezer appeared to be within the acceptable range
for 3 weeks. However, at the end of the fourth week,
measurements from these strips started to fall outside the
reference range and also had significantly increased variability.
Strips stored at ambient temperature gave acceptable measure-
ments after the first week (13 mm), after which values were
shorter than the reference range, which may be due to
increased paper and reagent hydrophobicity due to increased
desiccation. Strips stored at 37 °C were also below the
reference range in the first, third, and fourth weeks and may be
due to changes in hydrophobicity and thrombin activity.
However, without any further stabilization, the paper devices
appeared stable for up to 3 weeks at 4 to 6 °C. This
demonstrates the potential for long-term stabilization of
thrombin activity on paper to be achievable with the addition
of stabilizers, excipients, and processing techniques such as
lyophilization.
To be viable as an instrument-free device, particularly in
low-resource settings, assays must be capable of operation over
a range of ambient temperatures. Figure 6 shows operation of
the optimized assay from 25 to 40 °C. It can be seen that from
25 to 35 °C, the distance decreased and increased at 40 °C,
demonstrating that the impact of thrombin activity dominated
over other effects, such as changes in viscosity. Variations in
assay response to temperature can be addressed without
Table 2. Analytical Performance Parameters for Fibrinogen
Calibration Assays Across a Range of Sample Volumes
sample volume/μL slope (mg/mL/mm) r2 CV (%)
20 −4.701 0.927 6.51
22 −5.373 0.954 4.50
24 −4.579 0.999 11.57
26 −6.561 0.680 13.49
Figure 4. Calibration curve of concentration of fibrinogen standards
as determined by Yumizen G200 versus distance travelled after 300 s
for the optimized paper-based fibrinogen assay. Assay based on
deposition of 27 μL of 30 NIH/mL thrombin and 22 μL of the
sample (n = 3 repeats). Equation of the line, y = −5.058 ln(x) +
19.143 (r2 = 0.9822). Dashed lines: 95% confidence.
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temperature control using multiple, temperature-dependent
assay ranges.
The current assay has been developed and optimized in
plasma due to the absence of clinical sample availability during
COVID, which currently represents a limitation of demon-
stration of the device in whole blood. However, previous
devices based on polymer microfluidic chips which were
optimized in plasma were also found to be suitable for
operation in whole blood, and there are no obvious technical
limitations for the future demonstration of the current device
in a similar manner.4
■ CONCLUSIONS
A paper-based device for measuring fibrinogen in blood plasma
has been developed using wax-printed chromatographic paper
strips modified with an immobilized thrombin reagent.
Clotting of the blood plasma sample was induced by the
sample coming into contact with the thrombin reagent and the
distance travelled by the sample, and the sample fibrinogen
content had an inverse correlative relationship. The device was
capable of measuring plasma fibrinogen concentration in the
range of 0.5−7 mg/mL in less than 5 min. When packaged in
aluminum bags with a desiccant and stored in a fridge or
freezer, the device could remain active and functional for 3
Figure 5. Validation of the paper-based fibrinogen assay device in artificial plasma samples. (A) Correlation between the paper-based device and
Yumizen G200 fibrinogen assay reference method. A slope of 1.03, an intercept of 0.02, and an r2 of 0.9582 (20 samples, 3 repeats). (B) Bland−
Altman shows that all of the data points fall within the range between the upper limit of agreement (U LOA) and the lower limit of agreement (L
LOA), signifying adequate agreement between the two methods.
Table 3. Effect of Storage Conditions on Clotting Properties of Paper-Based Fibrinogen Assay Strips
storage conditions distance travelled by normal plasma/mm after number of days storage (n = 3)
day 0 day 7 day 14 day 21 day 28
freezer (−15 to −18 °C) 13.17 ± 0.76 12.83 ± 0.76 13.00 ± 1.00 12.67 ± 0.58 14.67 ± 3.40
fridge (4 to 6 °C) 13.50 ± 1.50 12.50 ± 0.50 13.00 ± 0.00 15.00 ± 3.12
ambient (18 to 23 °C) 13.00 ± 0.00 11.83 ± 1.76 11.17 ± 0.76 11.67 ± 1.04
oven (37 °C) 10.83 ± 0.58 12.67 ± 0.29 12.33 ± 1.04 10.67 ± 0.76
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weeks. The device was simple, low cost, robust, and sustainable
for use in low-resource environments and emergency settings.
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